This review evaluates resmetirom, the first FDA-approved treatment for Metabolic Dysfunction-Associated Steatohepatitis (MASH), a severe fatty liver disease. Resmetirom, a selective thyroid hormone receptor-beta agonist, reduces liver fat accumulation. Clinical data demonstrates it safely and effectively resolves MASH and improves liver fibrosis in non-cirrhotic patients, independent of weight-loss therapies. However, it is contraindicated for patients with full cirrhosis or untreated thyroid disorders.
This scoping review evaluated the real-world impact of front-of-package nutritional warning labels in Peru. These labels, which highlight high levels of sugar, sodium, and unhealthy fats, successfully disrupt automatic shopping habits. By providing immediate nutritional assessments, the warnings guide consumers away from ultra-processed foods and toward healthier alternatives, improving the nutritional quality of purchased goods. However, isolating the specific impact of these labels from concurrent health campaigns or economic factors remains challenging.
Researchers discovered that age-related cognitive decline in mice is linked to the gut bacterium Parabacteroides goldsteinii. As mice age, this bacterium accumulates and produces compounds that activate the inflammatory receptor GPR84 on immune cells. This inflammation impairs the vagus nerve, weakening gut-brain communication and reducing hippocampal activity, which causes memory deficits. Notably, scientists reversed this memory loss by targeting the bacteria with bacteriophages, blocking the GPR84 receptor, or directly stimulating the vagus nerve.